Projected Stock Price
No data available.
Projected Revenue
No data available.
Projected Earnings Per Share
Estimated quarterly earnings by December 31, 2027.
Price Target
No data available.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Viking Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
In addition to being able to interpret financial data, stock analysts have connections within the companies they cover that give them access to information retail investors do not have.
Therefore, analyst ratings can help you find opportunities in the market. However, they are guidelines more than recommendations. This is why it’s important to look at analyst ratings over a period of time.
If analysts change their ratings frequently, you should pay close attention to the company’s fundamentals. For example, has there been a significant change to the company’s earnings growth and/or debt?
You should also pay attention to the number of analysts covering a stock over the course of a year. In general, the more analysts who cover the stock give the consensus rating more credibility, but each individual rating less overall weight.
Analyst ratings are one data point for you to consider. Here are some strategies you can use to fine tune your research.
Look at more than one analyst and don’t hesitate to look at analysts that have differing views. This can help challenge any preconceived ideas you have about a stock and point out ways in which your thesis for owning or avoiding a stock may have changed.
Compare a stock’s rating with other stocks in its industry or sector. In some cases, a stock is simply superior to others in its sector. However, at other times, it could be overvalued based on investor sentiment instead of fundamentals.
How are the Fintel Analyst Ratings different?Analyst ratings by Fintel are presented in close to real-time to stay ahead of generalized information flow. Combined with target price estimates and revenue estimates for the company you have greater accuracy despite market volatility.
Date | Analyst | Prior | Latest Recommendation |
Action |
---|---|---|---|---|
2025-04-28 | Cantor Fitzgerald | Overweight | Initiate | |
2025-04-28 | Truist Securities | Buy | Buy | Reiterate |
2025-04-24 | Morgan Stanley | Overweight | Overweight | Maintains |
2025-04-24 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2025-04-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2025-04-08 | Goldman Sachs | Neutral | Initiate | |
2025-03-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2025-03-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2025-02-13 | Scotiabank | Sector Outperform | Initiate | |
2025-02-07 | Maxim Group | Buy | Buy | Maintains |
2025-02-07 | Citigroup | Neutral | Initiate | |
2025-02-07 | B. Riley Securities | Buy | Buy | Reiterate |
2025-02-06 | Raymond James | Strong Buy | Strong Buy | Maintains |
2025-02-06 | Piper Sandler | Overweight | Overweight | Maintains |
2025-02-06 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2025-01-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2025-01-10 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2025-01-08 | HC Wainwright & Co. | Buy | Buy | Maintains |
2024-12-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-12-18 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-12-02 | Piper Sandler | Overweight | Initiate | |
2024-11-27 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-11-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-11-22 | B. Riley Securities | Buy | Initiate | |
2024-11-05 | HC Wainwright & Co. | Buy | Buy | Maintains |
2024-10-24 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-10-09 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-09-25 | Oppenheimer | Outperform | Outperform | Reiterate |
2024-09-12 | Morgan Stanley | Overweight | Overweight | Reiterate |
2024-09-11 | JP Morgan | Overweight | Initiate | |
2024-07-25 | Raymond James | Strong Buy | Strong Buy | Maintains |
2024-07-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-06-27 | Morgan Stanley | Overweight | Initiate | |
2024-06-24 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-06-17 | Truist Securities | Buy | Buy | Maintains |
2024-06-04 | Maxim Group | Buy | Buy | Reiterate |
2024-06-04 | Raymond James | Strong Buy | Reiterate | |
2024-06-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-05-16 | Raymond James | Outperform | Strong Buy | Upgrade |
2024-05-16 | Truist Securities | Buy | Buy | Reiterate |
2024-04-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-03-27 | Oppenheimer | Outperform | Outperform | Maintains |
2024-03-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-03-26 | BTIG | Buy | Buy | Maintains |
2024-03-26 | Oppenheimer | Outperform | Outperform | Maintains |
2024-03-15 | Maxim Group | Buy | Buy | Reiterate |
2024-03-15 | BTIG | Buy | Buy | Maintains |
2024-03-15 | Stifel | Buy | Buy | Reiterate |
2024-03-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-03-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2024-03-07 | Jefferies | Buy | Initiate | |
2024-02-29 | Truist Securities | Buy | Buy | Maintains |
2024-02-28 | Oppenheimer | Outperform | Outperform | Maintains |
2024-02-27 | HC Wainwright & Co. | Buy | Buy | Maintains |
2024-02-27 | Raymond James | Outperform | Outperform | Maintains |
2024-02-14 | Stifel | Buy | Buy | Maintains |
2024-02-08 | Maxim Group | Buy | Buy | Maintains |
2023-12-04 | Truist Securities | Buy | Buy | Reiterate |
2023-10-02 | Truist Securities | Buy | Buy | Reiterate |
2023-08-08 | Stifel | Buy | Reiterate | |
2023-07-27 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2023-06-27 | Truist Securities | Buy | Buy | Reiterate |
2023-05-17 | Raymond James | Outperform | Outperform | Maintains |
2023-05-16 | BTIG | Buy | Buy | Maintains |
2023-05-16 | Stifel | Buy | Buy | Maintains |
2023-05-16 | Oppenheimer | Outperform | Outperform | Maintains |
2023-05-08 | HC Wainwright & Co. | Buy | Reiterate | |
2023-05-03 | Roth MKM | Buy | Maintains | |
2023-04-27 | Oppenheimer | Outperform | Reiterate | |
2023-04-27 | HC Wainwright & Co. | Buy | Maintains | |
2023-04-25 | Oppenheimer | Outperform | Maintains | |
2023-03-29 | Truist Securities | Buy | Maintains | |
2023-03-29 | Maxim Group | Buy | Maintains | |
2023-03-29 | Roth MKM | Buy | Maintains | |
2023-03-29 | Raymond James | Outperform | Maintains | |
2023-03-29 | BTIG | Buy | Maintains | |
2023-03-28 | Stifel | Buy | Maintains | |
2023-03-28 | Oppenheimer | Outperform | Maintains | |
2023-03-17 | Stifel | Buy | Initiate | |
2023-02-09 | Raymond James | Outperform | Maintains | |
2023-02-09 | HC Wainwright & Co. | Buy | Reiterate | |
2022-12-20 | Maxim Group | Buy | Maintains | |
2022-10-27 | Raymond James | Outperform | Maintains | |
2022-04-28 | SVB Leerink | Outperform | Maintains | |
2022-02-10 | Raymond James | Outperform | Maintains | |
2021-07-29 | Raymond James | Outperform | Maintains | |
2021-05-25 | Raymond James | Strong Buy | Outperform | Downgrade |
2020-10-29 | Raymond James | Strong Buy | Maintains | |
2020-08-31 | Chardan Capital | Buy | Maintains | |
2020-08-28 | HC Wainwright & Co. | Buy | Maintains | |
2020-06-05 | BMO Capital | Outperform | Initiate | |
2020-05-05 | Chardan Capital | Buy | Initiate | |
2020-05-04 | B. Riley FBR | Buy | Maintains | |
2020-05-01 | BTIG | Buy | Initiate | |
2020-05-01 | Raymond James | Strong Buy | Maintains | |
2020-02-27 | H.C. Wainwright | Buy | Reiterate | |
2019-07-16 | Oppenheimer | Outperform | Initiate | |
2019-06-25 | Stifel Nicolaus | Buy | Initiate | |
2019-03-29 | SVB Leerink | Market Perform | Outperform | Upgrade |
2019-03-14 | Raymond James | Strong Buy | Strong Buy | Maintains |
2018-12-12 | B. Riley FBR | Buy | Initiate | |
2018-11-19 | Raymond James | Outperform | Strong Buy | Upgrade |
2018-09-19 | Raymond James | Outperform | Outperform | Maintains |
2018-09-18 | H.C. Wainwright | Buy | Buy | Maintains |
2018-07-20 | SunTrust Robinson Humphrey | Buy | Initiate | |
2018-06-28 | Raymond James | Outperform | Initiate | |
2018-06-01 | Maxim Group | Buy | Buy | Maintains |
2018-06-01 | H.C. Wainwright | Buy | Buy | Reiterate |
2018-04-30 | William Blair | Outperform | Initiate | |
2017-11-21 | Roth Capital | Buy | Initiate | |
2016-05-24 | Maxim Group | Buy | Initiate | |
2016-04-07 | H.C. Wainwright | Buy | Initiate | |
2025-07-24 | Citigroup | Neutral | Neutral | Maintains |
2025-07-24 | Raymond James | Strong Buy | Strong Buy | Maintains |
2025-06-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
2025-08-19 | HC Wainwright & Co. | Buy | Buy | Reiterate |
Revenue Estimates
No data available.
Earnings Estimates
The forecasted annual earnings of Viking Therapeutics, Inc. in 2032-12-31 is 15.01 per share.
One part of an analyst’s rating is a profit (i.e., earnings) estimate for the current quarter and/or future quarters. The measurement given is earnings per share (EPS). EPS is a metric that indicates how much a company earned as represented by one share of its stock over a specific period (typically three months).
To understand the earnings per share calculation, you must understand net income. Net income is the amount of money a company has left over after deducting appropriate expenses and taxes from its revenues).
The formula for earnings per share is net income divided by the total number of outstanding shares (i.e., available for purchase). For example:
Company A has a net income of $100 million and forty million outstanding shares. The EPS calculation is as follows:
100,000,000/40,000,000 = $2.50 per share
Earnings per share is an essential metric for you to consider when deciding to buy a stock. After all, a company with high earnings per share is productive and generates revenue in excess of its operating costs.
However, it’s not the only metric you should use. Metrics like price-to-earnings and debt-to-equity add additional perspective about a company’s health.
You should also be sure to compare a company’s EPS with a company in its sector. However, when you do, be aware that EPS is different and more important than net profit by itself. You may see a company that has a rising net profit. But if its outstanding shares are also rising, then its EPS might be flat or even edging lower.
Update Frequency: Quarterly
Date | EPS Average (Quarterly) | Number of Analysts (Quarterly) | EPS Average (Annual) | Number of Analysts (Annually) |
---|---|---|---|---|
2025-09-30 | -0.43 | 15 | -- | -- |
2025-12-31 | -0.49 | 15 | -1.60 | 20 |
2026-03-31 | -0.52 | 5 | -- | -- |
2026-06-30 | -0.56 | 5 | -- | -- |
2026-09-30 | -0.62 | 5 | -- | -- |
2026-12-31 | -0.66 | 5 | -2.16 | 19 |
2027-03-31 | -0.49 | 3 | -- | -- |
2027-06-30 | -0.61 | 3 | -- | -- |
2027-09-30 | -0.67 | 3 | -- | -- |
2027-12-31 | -0.69 | 3 | -2.51 | 16 |
2028-12-31 | -- | -- | -1.82 | 9 |
2029-12-31 | -- | -- | 0.01 | 6 |
2030-12-31 | -- | -- | 4.51 | 6 |
2031-12-31 | -- | -- | 9.44 | 6 |
2032-12-31 | -- | -- | 15.01 | 6 |